You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

429 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Transplant Ineligible Multiple Myeloma
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
Sep 2022

Pages